Hep C p21 Inhibitors
Hep C p21 inhibitors act by disrupting crucial steps in the viral life cycle, effectively suppressing viral replication and reducing viral load in infected individuals. DAAs targeting HCV proteins such as NS3/4A protease, NS5A, and NS5B polymerase inhibit viral protease, RNA replication, and virion assembly, respectively, leading to potent antiviral effects.
Direct-acting antivirals (DAAs) are a class of small-molecule inhibitors that specifically target viral proteins essential for the replication of hepatitis C virus (HCV). These inhibitors, such as NS3/4A protease inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors, disrupt key steps in the viral life cycle, effectively inhibiting viral replication and reducing viral load in infected individuals. By blocking viral protein functions critical for HCV propagation, Hep C p21 inhibitors can play a crucial role in regard to HCV infection.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Telaprevir | 402957-28-2 | sc-364632 sc-364632A | 5 mg 50 mg | $849.00 $4665.00 | ||
Telaprevir is a direct-acting antiviral drug that inhibits the hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease, preventing cleavage of the viral polyprotein and thereby blocking viral replication. | ||||||
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $143.00 | 1 | |
Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which acts by incorporating into the viral RNA chain, leading to chain termination and inhibition of viral replication. | ||||||